Cerebral Infarction Acute Phase Treatment Of Oxygen Free Radical Scavenger Effect And Risk Analysis

Objective To observe the edaravone injection in treating acute cerebral infarction and security.Methods Randomized, placebo-controlled trials. 100 cases of patients with acute cerebral infarction. 50 cases of the treatment group given 30 mg of edaravone adding sodium chloride injection 100 mL, ivgtt, bid×14 d; the control group 50 cases, to give an equivalent sodium chloride injection by adding 10 mL sodium chloride injection 100 mL, ivgtt, bid×14 d; the basis for the treatment of patients with the same two groups. 1. Pre-treatment, treatment after 7, 14, 28 days for two patients with neurological deficit score and the NIHSS scale activities of daily living scale BI score, and 2 effects. Recorded two groups of patients before treatment, After the end of the day after the treatment of patients with prothrombin time, blood, liver and kidney function, enzyme checks, blood glucose changes and 2 comparison groups comparison 3. Record Group 2 within 3 weeks of treatment adverse events and comparison.Results 1. The two groups seven days after treatment NIHSS score and BI score differences between groups were statistically significant (P value <0.05); 14,21 days after treatment between the two groups NIHSS score and BI score of There were significant differences in statistical significance (P value <0.01); after treatment, 7,14 and 21 days of the NIHSS by a significant fraction of the rates were 18.00%, 50.00% and 70.00%, respectively, the control group 4.0%, 28.0% and 34.0%, the total effective rate were 60%, 92%, 94% in the control group were 44%, 72%, 82%, the differences between the two groups were significantly statistical significance (P value all <0.05). 2. The treatment group and control group before and after the prothrombin time before and after treatment, blood, liver and kidney function, enzyme checks, blood glucose changes were not statistically significant differences (P values> 0.05) between groups after treatment no significant differences (P values> 0.05). 3. The two groups the incidence of adverse events in treatment group were 4% and 6% of the control group, no significant difference between the two groups (P> 0.05).Conclusion Edaravone injection early use, can be effective in improving patients with acute cerebral infarction and neurological deficit in daily living skills, and prothrombin time, blood, liver and kidney function, enzymes, blood glucose had no effect, no significant adverse reactions . Can not explain Edaravone to treat diabetes, coronary heart disease, liver and kidney dysfunction diseases, such as oxygen free radicals...